Afatinib
Clinical Trials Overview
3 trials found
About Afatinib
Afatinib is an irreversible tyrosine kinase inhibitor that targets multiple members of the ErbB family of receptors. In colorectal cancer, afatinib is used off-label in select patients with EGFR-mutated tumors or as part of combination therapy with cetuximab in wild-type KRAS metastatic disease. The drug has been explored in tumor-agnostic approaches based on specific genomic alterations rather than tumor origin.
Category
Targeted Therapy
Brand Name
Gilotrif
Mechanism
Afatinib covalently binds to and irreversibly blocks EGFR (ErbB1), HER2 (ErbB2), and ErbB4 tyrosine kinases by forming a covalent bond with cysteine residues in the ATP-binding sites. This irreversible inhibition prevents autophosphorylation and downstream signaling through pathways including PI3K/AKT and RAS/RAF/MEK, ultimately leading to reduced tumor cell proliferation and survival.
3
Total Trials
0
Recruiting
1
Active
2
Completed
6,627
Total Enrollment
4
Countries
med_trials_trend_title
Number of trials started per year
med_trials_trend_flat
NCT02465060
Phase 2
Active
6,452 patients
Medications:
Adavosertib
Afatinib
Binimetinib
Capivasertib
Copanlisib
Crizotinib
Dabrafenib
Dasatinib
Defactinib
Erdafitinib
Fexagratinib
Ipatasertib
Larotrectinib
Nivolumab
Osimertinib
Palbociclib
Pertuzumab
Relatlimab
Sapanisertib
Taselisib
Trametinib
Trastuzumab
Ulixertinib
Vismodegib
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, l...
United States, Guam, Puerto Rico
NCT02795156
Phase 2
Completed
100 patients
With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients. If a genomic alteration is identified during profiling, it could help guide the choice of t...
United States
NCT01919879
Phase 2
Completed
75 patients
Medications:
Afatinib
Cetuximab
This is a multicentric, phase II and open label study.75 patients are expected to be randomized in 35 centers. The main objective is to assess the efficacy and safety of Afatinib -cetuximab combo versus cetuximab alone in treatment of patients with r...
France